LSD1去甲基化LINC01134通过SP1诱导p62转录介导肝细胞癌奥沙利铂耐药
该研究探讨肝细胞癌奥沙利铂耐药机制,发现LINC01134在耐药细胞中上调,高表达预示疗效差;LSD1去甲基化上调LINC01134,后者招募SP1激活p62抗氧化通路,体外体内调控耐药;靶向该轴可能克服耐药。
要点
- LINC01134在奥沙利铂耐药肝癌细胞中上调,高表达预示奥沙利铂疗效较差。
- LSD1去甲基化上调LINC01134,后者通过SP1激活p62抗氧化通路介导耐药。
- 靶向LINC01134/SP1/p62轴可能成为克服奥沙利铂耐药的策略。
核心结论
- LSD1/LINC01134/SP1/p62轴在肝细胞癌奥沙利铂耐药中起关键作用。
- 检测LINC01134表达有助于预测奥沙利铂疗效。
- 在初治患者中,靶向LINC01134/SP1/p62轴可能是克服奥沙利铂耐药的策略。
研究设计与样本
- 基础研究,采用RNA测序和FISH筛选奥沙利铂耐药相关lncRNA。
- 通过生存分析评估LINC01134和p62的临床意义。
- 采用荧光素酶、RIP、ChIP和ChIRP实验探索LINC01134调控p62的机制。
- 通过细胞活力、凋亡、线粒体功能与形态分析及异种移植评估LINC01134/SP1/p62轴对耐药的影响。
- 采用ChIP、细胞活力和异种移植实验鉴定LINC01134上调的去甲基化酶。
主要发现
- LINC01134是奥沙利铂耐药细胞中上调最显著的lncRNA之一。
- LINC01134通过招募转录因子SP1至p62启动子,经由p62激活抗氧化通路。
- LINC01134/SP1/p62轴在体外和体内通过改变细胞活力、凋亡和线粒体稳态调控奥沙利铂耐药。
- 去甲基化酶LSD1负责奥沙利铂耐药细胞中LINC01134的上调。
- 在肝细胞癌患者中,LINC01134表达与p62和LSD1表达正相关,SP1表达与p62表达正相关。
临床怎么用
- 评估肝细胞癌患者LINC01134表达可能有助于预测奥沙利铂疗效。
- 在初治患者中,靶向LINC01134/SP1/p62轴可能成为克服奥沙利铂耐药的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Oxaliplatin (OXA) is one of the most common chemotherapeutics in advanced hepatocellular carcinoma (HCC), the resistance of which poses a big challenge. Long noncoding RNAs (lncRNAs) play vital roles in chemoresistance. Therefore, elucidating the underlying mechanisms and identifying predictive lncRNAs for OXA resistance is needed urgently. METHODS: RNA sequencing (RNA-seq) and fluorescence in situ hybridization (FISH) were used to investigate the OXA-resistant (OXA-R) lncRNAs. Survival analysis was performed to determine the clinical significance of homo sapiens long intergenic non-protein-coding RNA 1134 (LINC01134) and p62 expression. Luciferase, RNA immunoprecipitation (RIP), chromatin immunoprecipitation (ChIP), and chromatin isolation by RNA purification (ChIRP) assays were used to explore the mechanisms by which LINC01134 regulates p62 expression. The effects of LINC01134/SP1/p62 axis on OXA resistance were evaluated using cell viability, apoptosis, and mitochondrial function and morphology analysis. Xenografts were used to estimate the in vivo regulation of OXA resistance by LINC01134/SP1/p62 axis. ChIP, cell viability, and xenograft assays were used to identify the demethylase for LINC01134 up-regulation in OXA resistance. RESULTS: LINC01134 was identified as one of the most up-regulated lncRNAs in OXA-R cells. Higher LINC01134 expression predicted poorer OXA therapeutic efficacy. LINC01134 activates anti-oxidative pathway through p62 by recruiting transcription factor SP1 to the p62 promoter. The LINC01134/SP1/p62 axis regulates OXA resistance by altering cell viability, apoptosis, and mitochondrial homeostasis both in vitro and in vivo. Furthermore, the demethylase, lysine specific demethylase 1 (LSD1) was responsible for LINC01134 up-regulation in OXA-R cells. In patients with HCC, LINC01134 expression was positively correlated with p62 and LSD1 expressions, whereas SP1 expression positively correlated with p62 expression. CONCLUSIONS: LSD1/LINC01134/SP1/p62 axis is critical for OXA resistance in HCC. Evaluating LINC01134 expression in HCC will be effective in predicting OXA efficacy. In treatment-naive patients, targeting the LINC01134/SP1/p62 axis may be a promising strategy to overcome OXA chemoresistance.
引用
- Ma L, Xu A, Kang L, et al. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC. Hepatology. 2021. PMID: 34322883. doi:10.1002/hep.32079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。